Document:

Exhibit 10.36

April 27, 2006

CONFIDENTIAL DRAFT

[*]=CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

	
  ScinoPharm Taiwan, Ltd.

  	
  Biddle Sawyer Pharma LLC

  
	
  No. 1 Nan-Ke 8th Rd.

  	
  21 Penn Plaza, 360 West 31st St.

  
	
  Tainan Science-based Industrial Park

  	
  New York, NY 10001-2727

  
	
  Tainan County 741, Taiwan

  	
  U.S.A.

  
	
  Attn:

  	
  [*]

  	
   

  
	
  CC:

  	
  [*]

  	
   

  

 

Re:  AMENDMENT NO. 4 TO TD-6424 SUPPLY AGREEMENT

Dear [*]:

Theravance, Inc., a
Delaware corporation, having a principal place of business at 901 Gateway Boulevard, South San Francisco, CA
94080, U.S.A. (“THERAVANCE”)
and ScinoPharm Taiwan, Ltd., a Taiwan Corporation, having a principal place of
business at No. 1, Nan-Ke 8th Road, Tainan Science-based Industrial Park, Shan-Hua, Tainan County 74144, Taiwan (“SCINOPHARM”), and Biddle
Sawyer Pharma LLC, having a principal place of business at 21 Penn Plaza, 360
West 31st Street,
New York, NY 10001-2727, U.S.A.
(“BSP”), previously entered into a Supply Agreement for Supply of TD-6424 dated
May 10, 2002, as amended (the “Agreement”).  THERAVANCE and SCINOPHARM
wish to further amend the Agreement to provide for SCINOPHARM to manufacture
and supply to THERAVANCE [*] of Product for
validation and launch supply as described in the attached Exhibit A—”Scope of Work” pursuant to the terms and
conditions of the Agreement, as amended hereby. 
Accordingly, the parties hereby agree as follows:

1.                                       The
parties agree that the attached Project Proposal, Exhibit A-1, is hereby added
to the Agreement to provide for manufacture of validation and launch supply
batches.  This new Exhibit A-1 does not
supersede any previous Exhibit A.

2.                                       The
parties agree that the attached Commercial Quality Agreement, Exhibit C-1, is
hereby added to the Agreement and is applicable to the

[*]=CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

 

new
Exhibit A-1 attached.  This revised
Exhibit C-1 does not supersede any previous Exhibit C.

3.                                       The
parties agree that the Packaging and Shipping Instructions attached to the
Agreement as Exhibit D are not applicable to the work to be performed
pursuant to the new Exhibit A-1. 
New Packaging and Shipping Instructions will be attached as a new
Exhibit D-1 by subsequent agreement of the parties.

4.                                       Except
as amended hereby, the Agreement remains in full force and effect. Capitalized
terms used herein and in the attached exhibits have the meanings given to them
in the Agreement unless otherwise define herein.

Please
indicate your agreement to the foregoing by signing the enclosed copy of this
letter where indicated below and returning it to me in the envelope provided.

	
   

  	
  Very truly yours,

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Arthur L. Campbell

  	
   

  
	
   

  	
  Arthur L. Campbell

  
	
   

  	
  Senior Vice President, Technical Operations

  
	
   

  	
  Theravance, Inc.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Accepted and Agreed:

  
	
   

  	
  SCINOPHARM Taiwan, Ltd.

  
	
   

  	
  No. 1 Nan-Ke 8th Rd.

  
	
   

  	
   

  	
  Tainan Science-based Industrial Park

  
	
   

  	
   

  	
  Tainan County 741, Taiwan

  
	
   

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Jo Shen

  	
   

  
	
   

  	
  Dr. Jo Shen

  
	
   

  	
  President & CEO

  
	
   

  	
   

  
	
   

  	
  Biddle Sawyer Pharma LLC

  
	
   

  	
  21 Penn Plaza, 360 West 31st St.

  
	
   

  	
  New York, NY 10001-2727

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ R.E. Chavkin

  	
   

  
	
   

  	
  R.E. Chavkin

  
	
   

  	
  President

  	
  5/11/06

  
						

 

 2
 

 

 

EXHIBIT
A-1

SCOPE OF WORK

[*]

[*]=CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 3
 

 

 

EXHIBIT C-1

 4
 

 

 

QUALITY AGREEMENT

BETWEEN

Theravance, Inc.

AND

ScinoPharm Taiwan, Ltd.

 5
 

 

 

TABLE OF
CONTENTS

	
  I.

  	
  Annual Product Reviews and Annual Reports

  
	
   

  	
   

  
	
  II.

  	
  Document and Reserve Sample Retention

  
	
   

  	
   

  
	
  III.

  	
  Deviations and Failure Investigations

  
	
   

  	
   

  
	
  IV.

  	
  Complaint and Adverse Event Handling

  
	
   

  	
   

  
	
  V.

  	
  Stability

  
	
   

  	
   

  
	
  VI.

  	
  Recalls

  
	
   

  	
   

  
	
  VII.

  	
  NDA Field Alerts

  
	
   

  	
   

  
	
  VIII.

  	
  Control Documents and Change Control Implementation

  
	
   

  	
   

  
	
  IX.

  	
  Label Copy Approval

  
	
   

  	
   

  
	
  X.

  	
  Regulatory Contacts

  
	
   

  	
   

  
	
  XI.

  	
  Audits by Theravance, Inc.

  
	
   

  	
   

  
	
  XII.

  	
  Raw Material/Packaging Component Testing/Vendor
  Audit of Raw Materials and Components

  
	
   

  	
   

  
	
  XIII.

  	
  Finished Product Testing

  
	
   

  	
   

  
	
  XIV.

  	
  Disposition of Materials

  
	
   

  	
   

  
	
  XV.

  	
  Validation/Qualification

  
	
   

  	
   

  
	
  XVI.

  	
  Sub-Contractors

  
	
   

  	
   

  
	
  XVII.

  	
  Restricted Compounds

  
	
   

  	
   

  
	
  XVIII.

  	
  Quality Contact List

  
	
   

  	
   

  
	
  XIX.

  	
  Roles & Responsibilities

  

 

 6

 

	
  THERAVANCE PRODUCTS:

  	
  TD-6424 HCl (DS for Telavancin)

  
	
   

  	
   

  
	
   

  	
   

  
	
  CONTRACT FACILITY:

  	
  ScinoPharm Taiwan, Ltd.

  
	
   

  	
  No. 1 Kan-Ke 8th Rd.

  
	
   

  	
  Tainan Science-Based Industrial Park

  
	
   

  	
  Tainan County 741, Taiwan

  

 

Theravance and ScinoPharm hereby agree to the
following terms relating to key quality and regulatory systems involved in the
manufacture and/or packaging of the above-noted products.

I.         ANNUAL
PRODUCT REVIEWS AND ANNUAL REPORTS

ScinoPharm shall prepare an Annual Product Review (“APR”)
for each Product as required by current Good Manufacturing Practices and
applicable regulations, including 21 C.F.R. §211.180(e). A
copy of the ScinoPharm APR for Theravance products must be forwarded to
Theravance QA within 10 business days after completion of the APR. The APR
shall be completed within 30 calendar days of its due date, established by a
schedule mutually agreed upon by both parties.

For Theravance NDA products, Theravance shall be
responsible for preparing the Annual Report as required by applicable
regulations, including 21 C.F.R.§§ 314.70(g)(3), 314.81(b)(2),
and/or 601.12(d), (f)(3). At least [*] before the Annual Report due date (i.e.,
the Product anniversary date), Theravance QA shall request in writing from
ScinoPharm the chemistry, manufacturing and controls data required for
submission of the Annual Report. ScinoPharm shall provide the information to
Theravance QA no later than 30 calendar days after the request.

II.       DOCUMENT
AND RESERVE SAMPLE RETENTION

All documents, records, and reports associated with
the manufacture, holding, storage, packaging, or testing of any Product lot,
including investigation reports, shall be retained by ScinoPharm for at least
[*] beyond the expiration date of the finished Product lot, or as otherwise
required by applicable law. All such documents, records, and reports must be
maintained by ScinoPharm in such a manner that they are (i) readily retrievable
and (ii) stored in an environment suitable to prevent damage or loss.
ScinoPharm shall provide copies of all such documents and information to
Theravance QA as reasonably requested. ScinoPharm will supply Theravance QA
with a complete set of the batch records for each lot of each product produced
for Theravance.

ScinoPharm shall retain samples from each incoming lot
of raw material used in the manufacture of any Product in an amount sufficient
to perform two complete repetitions of analytical testing as required by
material specification. ScinoPharm shall also retain samples of the packaged
finished Product for each lot of Product in an amount sufficient 

[*]=CERTAIN
INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS. 

 

 7
 

 

to perform two complete repetitions of full finished
Product analytical testing. ScinoPharm shall store retain samples under
conditions consistent with the labeling for a minimum of 2 year after the
expiration of the finished Product. Documentation of performance of examination
of reserve samples in accordance with 21 CFR § 211.170(b)
shall be maintained with stability data for Products.

III.      DEVIATIONS
AND FAILURE INVESTIGATIONS

Except as provided in Sections IV and V, ScinoPharm
must notify Theravance QA within 1 business days of the occurrence of a
confirmed out-of specification (OOS) result or major process deviation relating
to a Product. ScinoPharm shall make all Quality decisions regarding any such
out-of-specification result or major process deviation involving a Theravance
Product in consultation with Theravance QA. Any additional studies that may be
needed as part of the investigation are to be reviewed and approved by
Theravance prior to the initiation of the study. ScinoPharm is to provide
Theravance QA notification of any such out-of-specification result or major
process deviation involving split batches and provide copies of resulting
studies and investigations.

All investigations regarding OOS results or major
process deviations for Theravance Product must be completed, documented, and approved
by ScinoPharm and Theravance QA prior to issuance of a Certificate of
Compliance or a Certificate of Analysis pursuant to Section XIV. All
investigations regarding OOS results or major process deviations for Split lots
are to be provided to Theravance QA for review.

IV.      COMPLAINT
AND ADVERSE EVENT HANDLING

ScinoPharm shall investigate Product complaints
forwarded to ScinoPharm by Theravance. ScinoPharm shall comply with all
reasonable Theravance requests in connection with the investigation of any Product
complaint. ScinoPharm must provide Theravance with information regarding any
Product complaint investigation as reasonably requested by Theravance.

ScinoPharm shall complete and document each Product
complaint investigation within 30 calendar days after initial receipt of the
complaint by ScinoPharm, unless otherwise agreed by Theravance QA., whose
consent shall not be unreasonably withheld or delayed. If new information is
received, the ScinoPharm must respond within 30 calendar days of receipt of the
new information. If the investigation will exceed 45 calendar days, ScinoPharm
must provide Theravance QA with an interim report, including test results to
date and a target completion date, on or before the 45th calendar day of the investigation. ScinoPharm
must forward a copy of the final investigation report to Theravance QA within 5
business days after the completion of the investigation. Theravance QA shall be
responsible for determining, in its reasonable discretion, when a complaint
investigation has been completed and shall have sole responsibility for
responding to the complainant (if applicable).

ScinoPharm shall perform
preliminary investigations for all expedited complaints. Expedited complaints
involve but are not limited to allegations of tampering or mixed 

 

 8
 

 

product sourced
within the same manufacturing and/or packaging facility. Within 3 business
days, ScinoPharm must provide Theravance QA a preliminary investigation report
which shall include but is not limited to; review of manufacturing and/or
packaging records, review of analytical records and evaluation of retain
samples. Expedited complaint investigations must be completed within 14
calendar days of initial receipt of the complaint.

ScinoPharm shall notify Theravance QA of a confirmed
out-of-specification result pertaining to a complaint sample within 1 business
day of the occurrence of the out-of-specification result. Any
out-of-specification results relating to a Product complaint sample must be
investigated as described in Section V.

V.       STABILITY

Theravance and ScinoPharm shall document mutually
agreed-upon stability protocols, analytical methods and procedures, and
specifications for each Product. The stability protocol must detail, among
other information, specifications, storage conditions, test intervals, and a
description of approved container/closure systems.

ScinoPharm shall be responsible for conducting
stability testing pursuant to the applicable stability protocols. ScinoPharm
shall assure that an adequate number of samples, representative of lot
production, required for full stability testing through expiration are taken
and stored in accordance with conditions specified in the protocol.

If a stability study is not initiated within 30 days
of generation of release test result , the time zero data (data generated at
the start of the stability study) must be generated by new analysis rather than
extracted from release test results.

For stability samples requiring testing at weekly or
monthly (less than three months) intervals, the tests must be initiated within
seven (7) calendar days following the scheduled pull date. Daily and weekly
samples may be pulled one (1) business day prior to the scheduled pull date.

For stability samples requiring testing at the three
months or longer intervals (including at the expiry test station/label expiry
date) must be initiated within 14 calendar days following the scheduled pull
date.

Monthly stability samples must be pulled no earlier
than seven (7) days prior to the last day of the month in which the sample
expires.

ScinoPharm
must report any confirmed out-of-specification results relating to a Product
lot to Theravance QA within 1 business day of the occurrence. ScinoPharm must
use its best efforts to complete and document an investigation with regard to
any such out-of-specification result within 30 business days of the initial
out-of-specification result. If the investigation will exceed 30 business days,
ScinoPharm must provide Theravance QA with an interim report, including test
investigation. A copy of the final investigation report must be forwarded to
Theravance QA within 5 business days of completion of the 

 

 9
 

 

investigation. ScinoPharm must provide Theravance with
information regarding any investigation as reasonably requested by Theravance.

Any result obtained during stability testing that is
outside of recommended storage conditions (i.e. accelerated) or beyond expiry
is not considered to be within the definition of out-of-specification results.

ScinoPharm must investigate any significant (those
which indicate future testing will yield OOS results) trends regarding a
Product in an effort to determine the cause of the trend. Any such trends must
be reported to Theravance QA within 5 business days of identification of the
trend. ScinoPharm must provide Theravance QA with a report discussing the facts
and ScinoPharm’ conclusions within 5 business days of completion of the
investigation. ScinoPharm shall supply Theravance QA quarterly reports of all
stability results relating to Theravance Products. Theravance QA will provide
copies to the applicable markets.

VI.      RECALLS

Theravance shall have sole responsibility for
initiating and managing any Recall of Theravance Products, provided that
Theravance shall consult with ScinoPharm prior to initiating any Recall for
which it appears that ScinoPharm might bear expenses for the Recall. Upon
receiving direction from any governmental or Regulatory Authority having
jurisdiction to Recall any Product from the market, the receiving party shall
immediately notify the other party.

VII.    NDA FIELD ALERTS

Theravance shall be responsible for determining the
need for, and for filing, any NDA Field Alert Report and/or follow-up reports
relating to a Theravance Product. Theravance shall forward to ScinoPharm a copy
of any NDA Field Alert Report or follow-up report relating to a Product within
3 business days after its filing.

VIII.   CONTROL
DOCUMENTS AND CHANGE CONTROL IMPLEMENTATION

Any
change(s) made to the Specifications, including but not limited to the manufacturing
process and/or analytical methods which may affect the quality or performance
of the Product, exceed validation parameters or commitments made in regulatory
filings must be approved by Theravance QA., in writing, prior to implementation
for routine production or Release of any lot made after the revision. Documents
referenced in this Section must be amended as required by the Product
Application or license or as required by applicable laws, rules, regulations or
regulatory agencies. Copies of all revised documents applicable to Theravance products are to be provided to
Theravance QA at time of issuance. Theravance QA will provide copies to the
applicable markets.

 

 10
 

 

IX.      LABEL
COPY APPROVAL

In the packaging of the Products, ScinoPharm shall use
only labels and labeling approved in compliance with standards/specifications
provided by Theravance QA.

X.       REGULATORY
CONTACTS

Theravance shall be solely responsible for all
contacts and communications with any regulatory agency with respect to all
matters relating to Theravance Products.

Unless required by law or a regulatory agency,
ScinoPharm shall have no contacts or communication with any regulatory agency
regarding any Theravance Product without the consent of Theravance QA, which
consent shall not be unreasonably withheld or delayed. ScinoPharm shall notify
Theravance QA promptly, and in no event later than 1 calendar day, after
ScinoPharm receives any contact or communication from any regulatory agency
regarding a Product.

ScinoPharm shall provide Theravance QA with copies of
all communications received from or sent to any regulatory agency with respect
to any Product within 1 calendar day after receipt or sending of the
communication, as the case may be.

ScinoPharm shall inform Theravance QA of any inquiry
from a regulatory agency specifically relating to a Theravance Product and
shall allow a Theravance representative, at its discretion, to participate in
any further contacts or communications relating to a Product if reasonably
practicable. ScinoPharm will secure agreement from Theravance QA, which shall
not be unreasonably withheld or delayed, prior to making commitment to a
regulatory agency regarding the Products. ScinoPharm shall comply with all
reasonable requests and comments by Theravance with respect to all contacts and
communications with a regulatory agency relating to a Product.

ScinoPharm must make available to Theravance any data
and/or information, including samples, required to ensure Theravance’s
compliance with its regulatory filings. Theravance reserves the right to submit
such data to regulatory agencies as required to maintain compliance with its
regulatory filings.

XI.      AUDITS BY THERAVANCE, INC.

Theravance shall have access to ScinoPharm facilities
at a mutually agreeable time for the sole purpose of auditing ScinoPharm
operations compliance with cGMPs and the content of this Agreement. Theravance
shall be permitted to periodically review ScinoPharm facilities, equipment,
process, and records associated with the Product or as necessary as follow-up
to failure investigations and/or audit observations.

XII.    RAW MATERIAL/PACKAGING COMPONENT
TESTING/VENDOR AUDIT OF RAW MATERIALS AND COMPONENTS

ScinoPharm
will perform all the required raw material and packaging component testing
using approved analytical methods. ScinoPharm shall receive, sample, test,
release, hold, 

 

 11
 

 

and store any raw material or packaging component
supplied for the manufacturing or packaging of the Product in accordance with
current Good Manufacturing Practices, Theravance specifications, and applicable
laws, rules, and regulations. ScinoPharm
shall be responsible for the rejection of all raw materials and packaging
components that do not conform with the applicable specification. ScinoPharm
will be responsible for the destruction of all excess or rejected raw materials
and packaging components as per the company’s applicable approved standard
operating procedures.

ScinoPharm is responsible for auditing the vendor of
any material that is supplied by ScinoPharm for the Product and will provide
Theravance with an audit status statement upon request. If the vendor of any
material for the Product has been previously audited and approved by
Theravance, ScinoPharm is not required to perform a re-audit. Theravance, Inc.
is responsible for auditing the vendor of any material that is supplied by
Theravance, Inc. and will provide ScinoPharm with an audit status statement
upon request. 

XIII.   FINISHED
PRODUCT TESTING

ScinoPharm will perform finished product testing using
the approved analytical methods. Any material supplied by or for Theravance
shall be manufactured, held, stored, packaged, and tested in accordance with
current Good Manufacturing Practices, Theravance specifications, and applicable
laws, rules, and regulations.

XIV.   DISPOSITION
OF MATERIALS

Subject to the terms of this Agreement, ScinoPharm
shall be responsible for determining whether to release or reject any
Theravance Product lot to Theravance. Before shipment by ScinoPharm to
Theravance of any Product lot, ScinoPharm shall provide Theravance QA with
copies of a Certificate of Compliance, a Certificate of Analysis and all
investigation reports relating to the Product lot and await receipt of
Theravance Release Authorization for shipment of that lot to Theravance for distribution,
further processing, and/or further packaging. Final lot disposition for
non-U.S. Theravance products will be done by the responsible QP or Quality
Authority for that market.

A Certificate of Analysis (C of A) is a comprehensive listing of all analytical tests, test procedures, specifications
and test results corresponding to those specifications for an individual lot of
product.

A Certificate of Compliance is a certification that
the product was processed, packaged and stored in accordance with cGMPs,
specifications and ScinoPharm’s SOPs. Additionally, the certification states
that the product meets all specifications, no investigations remain unresolved
and all reconciliations and accountability have been satisfactorily completed.
The certificate must include the Product identification, lot number, expiration
date and final product yield.

Disposition
of any excess, expired or rejected materials shall be in accordance with
procedures for certified destruction or other means. Rejection of any lot of
finished product will be completed as per the approved SOP of the site
completing the rejection.

 

 12

 

 

ScinoPharm shall make documentation or completion of
disposition available to Theravance upon reasonable request.

ScinoPharm shall prepare
any Theravance Product in accordance with the NOTE for Guidance on Minimizing
the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and
Veterinary Medicinal Product, published by the European Agency for the
Evaluation of Medicine (EMEA).

ScinoPharm shall provide
Theravance a TSE certificate annually for each Theravance Product.  ScinoPharm is responsible for procuring TSE
certificates of all materials used in the preparation Theravance Product.

Within thirty (30) days
after notification that the Product does not meet the Specifications by
Theravance, ScinoPharm has the right to request that both Parties shall conduct
a joint investigation to determine whether such Product meets such
Specifications.  This joint investigation
may include, upon agreement by the Parties, the assistance of outside
consultants.  If resolution cannot be
reached, the Parties agree to send a sample of the Drug Product in question to
an independent testing laboratory suitable to both Parties.  The cost of this testing will be paid by the
Party that was in error with respect to whether or not the Product meets the
Specifications.

ScinoPharm will correct
or replace, at no additional cost to Theravance, any batch of Drug Product that
does not conform to the Specifications, provided that such failure to conform
does not arise from a change in the process agreed to by Theravance or from
Theravance’s negligence.  If Product must
be returned by Theravance due to a failure of the Product to meet the
Specifications, ScinoPharm  shall, at
Theravance’s sole option; (i) reprocess the Drug Product, if applicable, (ii)
reimburse Theravance for the cost of all raw materials, starting materials and
components provided by Theravance and return transportation and insurance
costs, or (iii) replace the rejected Product as soon as possible at no
extra cost to Theravance.

XV.         VALIDATION/QUALIFICATION

Theravance and ScinoPharm
agree to the following Validation/Qualification Policy for the Product:

1.                                       Equipment
and facilities/utilities qualification/validation shall be performed for
process, packaging, analytical methods, cleaning, and computerized systems.

2.                                       Validation
shall consist of prospective performance on at least three consecutive
production batches.  Validation must be
conducted with commercial production/analytical processes and equipment.

3.                                       Revalidation
shall be performed for significant changes to existing manufacturing process,
packaging, analytical, etc. (as determined by Theravance QA).  The number of batches required for
revalidation will be determined by Theravance and ScinoPharm based on the
significance of the change.

 13
 

 

 

4.                                       Theravance colleagues shall have the right to be
present during the manufacture of validation and launch batches.

5.                                       Cleaning
Validation shall involve three replicate runs of cleaning procedure for contact
equipment during Process and Packaging Validation, except for dedicated
equipment which will require one verification run of the cleaning procedure.

6.                                       Theravance shall have the right to require full or
partial revalidation for changes made to the validated product, based on a
shared change control system and an assessment of the significance of the
change.  ScinoPharm will notify
Theravance QA of any planned changes to a validated process or associated
procedures sufficiently in advance to allow Theravance an opportunity to assess
the change(s) and any ramifications.  No
changes shall be made to the validated process or product without prior written
consent of Theravance QA.  Copies of
associated documents are to be provided to Theravance QA.  Theravance QA will forward these documents to
the applicable markets.

XVI.        SUB-CONTRACTORS

ScinoPharm will not use
sub-contracted service providers for manufacturing, packaging, testing, storage
or distribution of the Products without prior written notice and concurrence of
Theravance QA., which concurrence shall not be unreasonably withheld or
delayed.

XVII.      RESTRICTED COMPOUNDS

ScinoPharm shall not use
Theravance Product equipment to manufacture a product containing any of the
following compounds without Theravance QA written prior consent:

[*]

XVIII.               QUALITY CONTACT LIST

THERAVANCE,
INC.

	
  Name

  	
   

  	
  Telephone

  Number

  	
   

  	
  Fax. Number

  	
   

  	
  E-mail Address

  
	
  [*]

  	
   

  	
  [*]

  	
   

  	
  [*]

  	
   

  	
  [*]

  
	
  [*]

  	
   

  	
  [*]

  	
   

  	
  [*]

  	
   

  	
  [*]

  

 

[*]=CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS. 

 

 14
 

 

 

CONTRACTOR OPERATIONS

 

	
  Name

  	
   

  	
  Telephone

  Number

  	
   

  	
  Fax. Number

  	
   

  	
  E-mail Address

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 15
 

 

 

XIX.        ROLES & RESPONSIBILITIES

	
  Process

  	
   

  	
  ScinoPharm

  	
   

  	
  Theravance

  	
   

  
	
  Raw Materials & Packaging Components

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Ordering

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Specifications

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Sampling

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Release

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Manufacturing/Packaging Process Control

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Sampling

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Testing

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Finished Product

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Retain Sampling

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Retain Storage

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Testing

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Batch Records

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Review of Batch Records

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Final Release to Distribution

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Storage

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Shipment

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Quality Assurance

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Annual Product Review

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Annual Report

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  Change Control

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Contact List

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Deviations/Investigations

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Drug Listing

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  Internal Audits

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  NDA Changes

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  Product Complaints

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Recalls and Field Alerts

  	
   

  	
   

  	
   

  	
  X

  	
   

  
	
  Regulatory Audits

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Stability Testing

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Monitoring of Operations

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Quality Control

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Quality Inspection

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Rejects

  	
   

  	
  X

  	
   

  	
   

  	
   

  

 

 16
 

 

 

	
  Documents

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Audit Report

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Batch Record

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Certificate of Analysis

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Certificate of Compliance

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Investigation/Deviation
  Reports

  	
   

  	
  X

  	
   

  	
  X

  	
   

  
	
  Master Batch Record

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Packaging Record

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Validation Protocol

  	
   

  	
  X

  	
   

  	
   

  	
   

  
	
  Validation Report

  	
   

  	
  X

  	
   

  	
   

  	
   

  

 

In Witness Whereof, the
parties have caused this Agreement to be duly executed in their respective
names and on their behalf, as of the date first above written.

Theravance, Inc.

	
  /s/ Arthur L. Campbell

  	
   

  
	
  By:

  	
  Arthur L. Campbell

  
	
  Title:

  	
  Senior Vice President, Technical Operations

  
			

 

ScinoPharm
Taiwan, Ltd.

	
  By:

  	
  /s/ Younan Shih

  	
   

  
	
  Title: V.P.
  Quality & Regulatory

  

 

Biddle Sawyer Pharma LLC

	
  By:

  	
  /s/ R.E. Chavkin

  	
   

  
	
  Robert E.
  Chavkin

  
	
  President

  

 

 17Exhibit 10.01

 

REVOLVING FINANCING AGREEMENT

(SAL w/ ELT)

 

REVOLVING
FINANCING AGREEMENT, dated as of July 1, 2006, among WALDEN UNIVERSITY, INC,
whose principal office is located at 1001 Fleet Street, Baltimore, MD 21202
(herein called the “Borrower”), WELLS FARGO BANK, NATIONAL ASSOCIATION, solely
in its capacity as eligible lender trustee for the Borrower (herein called the “Trustee”),
with a corporate trust office located at 7077 Bonneval Road, Suite 400,
Jacksonville, FL 32216, and SALLIE MAE, INC., whose principal office is located
at 12061 Bluemont Way, Reston, VA 20190 (together with its successors and
assigns, herein called “Sallie Mae”).

 

RECITALS

 

WHEREAS,
the Borrower has requested advances from Sallie Mae in an aggregate amount of
up to $100,000,000, which amount will be used by the Borrower in conducting its
student lending activities; and

 

WHEREAS,
Sallie Mae desires to encourage the Borrower’s lending activities by providing
advances on the terms and conditions hereinafter set forth;

 

NOW
THEREFORE, in consideration of the premises and the promises hereinafter set
forth, the Borrower and Sallie Mae agree as follows:

 

SECTION 1. DEFINITIONS

 

For
purposes hereof—:

 

1.1           “Act” means Part B of Title IV of the Higher Education Act of 1965, as
amended (20 U.S.C. Section 1071 et seq.), and the regulations
promulgated thereunder.

 

1.2           “Advance” or “Advances” means, respectively, any and all of the loans
provided for in Section 3 of this Agreement, and any renewals or extensions
thereof.

 

1.3           “Agreement” means this Revolving Financing Agreement providing for
Advances to the Borrower upon the terms and conditions specified herein.

 

1.4           “Assignment” means an assignment by the Borrower and the Trustee to
Sallie Mae in the form of Annex D-2 hereto, covering the Security, duly
executed and completed, together with any supplemental assignments from time to
time delivered pursuant to this Agreement.

 

1.5           “Borrower” means Walden University, Inc. and its permitted successors
and assigns.

 

1.6           “Borrowing Date” means any Business Day during the Borrowing Period;
provided, however, that unless otherwise agreed by Sallie Mae, there shall be
no more than one Borrowing Date in any calendar week.

 

1

 

1.7           “Borrowing Period” means the period beginning on the date of this
Agreement and ending on the Maturity Date.

 

1.8           “Business Day” means any day (i) on which commercial banks located in
New York, NY are not required or authorized to remain closed, (ii) that is not
a Saturday, Sunday, or legal holiday, (iii) that is a day of the year on which
the New York Stock Exchange is not closed, and (iv) that is a day of the year
on which Sallie Mae is not closed.

 

1.9           “Commitment” means the obligation of Sallie Mae to make Advances to the
Borrower in the amounts provided in Section 3 hereof.

 

1.10         “Compliance Certificate” means a certificate in the form of Annex C
hereto, duly completed in accordance with its terms and the applicable
requirements of this Agreement, and signed by an authorized officer of the
Borrower.

 

1.11         “Default” means a default specified in
Section 9 hereof.

 

1.12         “ECFC” means SLM Education Credit Finance Corporation and its
successors and assigns.

 

1.13         “Eligible Insurer” means a State or non-profit private institution or
organization with which the Secretary has an agreement under Section 428(b) of
the Act, that is deemed acceptable by Sallie Mae.

 

1.14         “Eligible Loan” means an Insured Loan that bears interest at the
highest rate permitted under the Act for that loan at the time the loan was
made, and in respect of which no payment of principal or interest is at the
time overdue for more than thirty (30) days, and which is serviced by Sallie
Mae, in its capacity as Servicer.

 

1.15         “ExportSS Agreement” means the ExportSS® Agreement dated July 1, 2006,
among ECFC, Sallie Mae, the Borrower, and the Trustee, or any replacement,
extension, or renewal thereof, as amended from time to time, that provides,
among other items, for the sale to ECFC of all of the Insured Loans that are
financed, in whole or in part, with the proceeds of any Advance.

 

1.16         “FFELP Loan” means an education loan made under the Act.

 

1.17         “Financials” mean, collectively, balance sheets of the Borrower and the
related statements of earnings or receipts and of source and application of
funds, together with the notes thereto, prepared in accordance with generally
accepted accounting principles, consistently applied, with (A) with respect to
the annual statements, opinions thereon of independent certified public accountants,
and (B) with respect to quarterly statements, certifications from the financial
officers of the Borrower responsible for the preparation of the Financials, to
the effect that the Financials have been prepared in accordance with generally
accepted accounting principles applied on a consistent basis, and fairly
present the financial condition of the Borrower as at their date and the
results of its operations for the period then ended.

 

2

 

1.18         “Insured Loan” means a student loan made after the date of this
Agreement under the Act (i) in connection with attendance by a student at a
graduate or professional school that is part of Walden University, Inc., (ii)
that is insured by an Eligible Insurer to the maximum extent provided for under
the Act, and (iii) that is reinsured by the Secretary as to principal and
interest to the extent provided in the Act.

 

1.19         “LARS form” means the “Lender’s Request for Payment of Interest and
Special Allowance” that is filed with the Department of Education (previously
known as ED Form 799), or any replacement thereof or substitution therefor.

 

1.20         “Maturity Date” means the later of (i) May 31, 2009, or (ii) the date
of the last scheduled sale of Eligible Loans under the ExportSS Agreement.

 

1.21         “Note” shall mean the promissory note evidencing the Advances to be
made under Section 3 hereof.

 

1.22         “Obligation” or “Obligations” means, collectively, the principal of and
interest on the Advances and all other amounts from time to time owed by the
Borrower to Sallie Mae or ECFC, whether or not arising under this Agreement or
thereafter incurred.

 

1.23         “Request Register” means a form sent by Sallie Mae, in its capacity as
Servicer, to the Borrower that details the pending disbursements of Insured
Loans for a specific disbursement date.

 

1.24         “Sallie Mae” means Sallie Mae, Inc. and its successors and assigns.

 

1.25         “Secretary” means the United States Secretary of Education, or his
successor or representative, acting under the Act.

 

1.26         “Security” shall have its meaning as defined in Section 8 of this
Agreement.

 

1.27         “Servicer” means a servicing agent designated by the Borrower to
originate and service the Insured Loans that is approved by Sallie Mae in
accordance with the provisions of Section 8 hereof.

 

1.28         “Student Note” means, with respect to any Insured Loan that is at the
time included in the Security, collectively: (1) each and every promissory note
executed and delivered by the student borrower to evidence such loans or any
portion thereof, and (2) each and every certificate of insurance or other
instrument issued to evidence the insurance of such loan or any portion thereof
(A) by the Secretary pursuant to the Act or (B) by an Eligible Insurer or
instrumentality or official thereof.

 

1.29         “Trustee”
means Wells Fargo Bank, National Association, solely in its capacity as eligible
lender trustee for the Borrower, and any person or entity serving as a
replacement or substituted trustee.

 

3

 

SECTION 2. REPRESENTATIONS AND COVENANTS OF THE BORROWER

 

A.
The Borrower hereby represents, covenants, and warrants to Sallie Mae that:

 

(1)           The Financials for the calendar year
ending on December 31, 2005 and the quarterly period ending on March 31, 2006,
respectively, are complete and correct and fairly present the results of the
Borrower’s operations for the periods ending on said dates, and are in
conformity with generally accepted accounting principles applied on a consistent
basis. The Borrower has no material contingent liabilities, liabilities for
taxes, or unusual forward or long-term commitments not disclosed by, or
reserved against, in said Financials or the notes thereto, and at the present
time there are no material unrealized anticipated losses from any unfavorable
commitments of the Borrower.  Since March
31, 2006, there has been no material adverse change in the financial condition
of the Borrower from that shown by said Financials as at that date.

 

(2)           The Borrower is a for profit
corporation duly chartered, validly existing and in good standing under the
laws of the State of Florida, and is duly qualified to transact operations in
all places where such qualification is necessary; and the Borrower has the necessary
power to enter into and perform this Agreement and the Assignment and to borrow
hereunder.

 

(3)           There are no suits, proceedings, or
other matters pending, or to the knowledge of the Borrower threatened, against
or affecting the Borrower or any of its property before any court or by or
before any governmental authority, which, if adversely determined, would have a
material adverse effect on the financial condition or operations of the Borrower,
or its ability to make and perform this Agreement or the Note. The Borrower has
advised Sallie Mae of all material pending investigations and examinations of
the Borrower by regulatory or other governmental authorities, other than
financial audits and other similar examinations conducted by oversight
authorities on a regular basis with respect to other institutions similarly
situated. Borrower agrees to advise Sallie Mae promptly in the event the
Borrower becomes aware that any such suits, proceedings, investigations, or
examinations are instituted while the Agreement or any Advances that may be
made thereunder are outstanding.

 

(4)           The Borrower has advised Sallie Mae
of all pending negotiations, discussions, agreements, and contracts relating to
the consolidation, merger, sale, or conveyance of Borrower or any material part
of its assets, or the sale or conveyance of any controlling interest in
Borrower, and, so long as the Agreement remains outstanding, agrees to advise Sallie
Mae promptly of any such negotiations, discussions, agreements and contracts
that may arise from time to time.

 

(5)           The making and performance of this
Agreement have been duly authorized by all necessary action and will not
contravene any provision of law or of the Borrower’s governing documents or of
any indenture or other agreement or instrument to which the Borrower is a party
or by which the Borrower or its property may be bound or affected.  Any approvals, if necessary, of any regulatory
authority and/or holders of the Borrower’s income capital certificates have
been obtained.

 

4

 

(6)           No Default has occurred on the date
of this Agreement or will occur by reason of the making of any Advance or the
granting of the Security therefor.

 

(7)           The Borrower does not, and will not,
discriminate on the basis of race, sex, color, creed, or national origin.

 

(8)           The Trustee does not, and will not,
require that, as a condition to the receipt of a loan intended to be an Insured
Loan, the respective student borrower or his family maintain a business
relationship with the Trustee, except that this representation shall not apply
with respect to any loan made by a credit union, savings and loan association, mutual
savings bank, institution of higher education or by any other borrower with
less than $75,000,000 in deposits.

 

(9)           The Borrower has advised Sallie Mae
of any current limitations imposed by the Secretary or an Eligible Insurer as
to the amount or number of Insured Loans the Borrower or the Trustee may make
from time to time. The Borrower agrees promptly to advise Sallie Mae in the
event any such limitations are imposed.

 

(10)         The Borrower agrees to advise Sallie
Mae promptly in writing of any material change in its operations, management,
or financial condition.

 

B.            With respect to each of the items
now or hereafter included in the Security, the Borrower hereby represents,
covenants and warrants:

 

(1)           So long as any Obligations remain
outstanding, the Borrower at all times will be the sole beneficial owner of the
Security and no lien, charge, encumbrance or other security interest will at
any time exist upon the Security (other than interests of the Secretary or an
Eligible Insurer in connection with the insurance of Insured Loans, or the lien
of Sallie Mae or ECFC).

 

(2)           The Borrower has, and will continue
to have, the full right and authority to pledge the Security (or to cause the
Trustee to pledge legal title to the Security) pursuant to the Assignment and
to consummate the other transactions contemplated herein.

 

(3)           The Borrower has exercised, and so
long as any Advance remains outstanding will exercise, due diligence and
reasonable care in the administration, servicing and collecting of Insured
Loans from time to time included in the Security; provided, however, that for all of the Insured Loans that
are originated and serviced by Sallie Mae, in its capacity as Servicer,
Borrower shall be deemed in compliance with this requirement.

 

(4)           All Insured Loans from time to time
delivered to Sallie Mae will be duly insured (i) by the Secretary under the Act
or (ii) by an Eligible Insurer and reinsured by the Secretary, and will be
entitled to the benefits of such insurance and of any special allowances and/or
supplemental payments available to loans of such character under or pursuant to
the Act or any applicable state legislation. The Borrower will not take or omit
to take any action that would, under the Act, any applicable state legislation,
regulations

 

5

 

promulgated
thereunder, or rules or decisions of the Secretary or of any Eligible Insurer
or any instrumentality or official thereof, jeopardize such insurance or other
benefits.

 

(5)           The rights of the Trustee to any and
all benefits of insurance and to any special allowances and/or supplemental
payments available in respect of Insured Loans included in the Security that
are insured by an Eligible Insurer may be transferred to Sallie Mae pursuant to
applicable legislation, regulations, rulings, or decisions, and Borrower shall
give the necessary notice (or shall cause the Trustee to give the necessary
notice) to Eligible Insurers or other authorities and take such other actions
as may be necessary to transfer and perfect and otherwise preserve Sallie Mae’s
rights under the Agreement to such insurance benefits, special allowances and/or
supplemental payments.

 

SECTION 3. FINANCING COMMITMENT

 

Sallie
Mae agrees, subject to and upon the terms of this Agreement, to make Advances
to the Borrower from time to time as requested on the Borrowing Dates, but not
later than the Borrowing Period, in an aggregate amount at any one time
outstanding of up to ONE HUNDRED MILLION AND 00/100 DOLLARS ($100,000,000).  The total of all such Advances shall not
exceed an aggregate principal amount at any one time outstanding equal to the
amount for which Security has been pledged pursuant to and in accordance with
the minimum collateral levels of Section 8.A hereof. Additionally, following
the expiration of the Commitment Period set forth in the ExportSS Agreement,
each Advance on any particular Borrowing Date shall be limited to an amount
equal to the aggregate amounts that are to be disbursed on such Borrowing Date
as subsequent disbursements on Eligible Loans that already had first
disbursements made prior to the end of such Commitment Period.

 

The
following provisions shall apply to Advances under this Section 3:

 

A.   Form
of Note. The Advances shall be evidenced by a Note in the form of Annex A
hereto having a stated principal amount not to exceed One Hundred Million and
00/100 Dollars ($100,000,000). The Note shall be dated as of July 1, 2006, and
shall be payable to Sallie Mae or order on or before the Maturity Date.

 

B.   Interest.
Interest shall be paid on the aggregate principal balance of the Advances
outstanding at the end of each day during the period commencing on the date of
the Note and ending on the date said principal balance outstanding is paid in
full at a rate per annum, to the extent permitted by law, that shall be
determined as to each such day by adding a specified percentage (the “Margin”)
to the weighted average of the bond equivalent rates of the quotes of the
3-month commercial paper (financial) rates in effect for each of the days in
such quarter as reported by the Federal Reserve in Publication H-15 (or its
successor) for such 3-month period (computed on the basis of actual days
elapsed and a year of 365 or 366 days, as appropriate).  The Margin shall be fifty one-hundredths
percent (0.50%) per annum from the date of this Agreement until all Obligations
are paid in full

 

For
purposes hereof, the bond equivalent rates of the quotes of the 3-month
commercial paper (financial) rates shall be determined by (A) multiplying the
3-month commercial paper (financial) rate by the actual number of days in the
year (365 ordinarily, but

 

6

 

366 if February 29 falls
within the year), and then dividing the result in (A) by (B) the result of the
following two calculations: (i) multiplying the 3-month commercial paper
(financial) rate by 90, and (ii) subtracting the product determined in clause
(i) from 360. The resulting rate shall then be rounded to five (5) decimal
places. For any day that is a Saturday, Sunday, or business holiday, the rate
shall be determined by using the rate on the immediately preceding Business
Day.

 

Interest
on the Advances shall be accrued and shall be due and payable on the first
Business Day following the last day of each month, except that the final
interest payment on the Advances shall be due and payable on the same day as the
principal thereof.

 

C.   Payment,
etc. All payments of principal and interest in respect of the Advance or
Advances and other charges made under this Agreement shall be made in lawful
money of the United States in immediately available funds to the designated
agent of Sallie Mae.  Interest on the
Advances and other charges shall be calculated on the basis of actual days
elapsed and a year of 365 days or 366 days, as applicable. If any principal of
or interest on the Advances falls due on a Saturday, Sunday, or legal holiday
at the place of payment, then such due date shall be extended to the next
succeeding full Business Day at such place, and interest, in the case of a principal
payment, shall be payable in respect of such extension.

 

Borrower
agrees, until all Obligations have been fully repaid, to cause the Trustee to
direct the Secretary, and any person or entity acting on behalf of the
Secretary, to make all payments that would otherwise be paid to the Trustee or
the Borrower pursuant to the LARS form, to an account designated by Sallie Mae
in lieu of making such payments to the Trustee or the Borrower. To the extent
Sallie Mae receives payment from the Secretary with respect to any particular
calendar quarter (or part thereof) reflected on such LARS form before Borrower
pays interest that is then owed on the Advances, and provided no affiliate of
Sallie Mae has purchased a participation interest in the Insured Loans, Sallie
Mae will apply such LARS form payment against the interest payment that is due and
payable. If the LARS form payment received from the Secretary exceeds the
amount that Sallie Mae applies against the interest payment owed by the
Borrower, Sallie Mae will promptly refund the amount of the excess to the
Borrower by electronic transfer of funds to Borrower’s designated account. If
the LARS form payment received from the Secretary is insufficient to pay the
interest payment that is owed by the Borrower, the Borrower will remain
obligated to make such interest payment when due.

 

D.   Prepayments.
The Borrower (i) may, at its option, prepay the Advances, in whole or in part
and without penalty, at any time, and (ii) shall be required, from time to
time, to prepay portions of the Advance as required by Sections 3.F and 3.G
below. Except for prepayments with the proceeds of refunds or cancellations of
Insured Loans, or the sale of Insured Loans by the Borrower to ECFC, any
prepayment made shall be in the minimum amount, of Ten Thousand Dollars
($10,000.00) or in multiples thereof. Any principal amount so prepaid shall be
added to the unutilized commitment remaining hereunder and maybe re-borrowed.

 

In
addition to the above-described prepayment provision, the Borrower is also
subject to the mandatory prepayment provisions contained herein, including, but
not limited to, Sections 3.F, 3.G, 8.A.(2), 11.E, 11.F and 11.G hereof.

 

7

 

E.   Additional
Payments. Overdue principal in respect of the Advances shall bear interest
at a rate per annum two percent (2%) above the rate in effect thereon at the
time the same becomes overdue. Overdue interest in respect of the Advances, at
the time it becomes overdue, shall be added to the principal amount of the
Advances and shall bear interest at the same rate as overdue principal.

 

F.   Loan
Sale Proceeds. All proceeds of sales of Insured Loans under the ExportSS
Agreement will be applied as follows:

 

(i)
the portion of the proceeds of such sales that represents the Principal Balance
(as defined in the ExportSS Agreement) of the Insured Loans that are sold will
be applied to prepay the principal portion of the Advance outstanding under
this Agreement, and

 

(ii)
the portion of the proceeds of such sales that represents premiums, accrued
interest, or other amounts that are payable in connection with such sales will
be applied to repay any amounts outstanding under this Agreement or the
ExportSS Agreement that are payable and overdue, and any excess will be paid to
the Borrower by electronic funds transfer.

 

G.   Mandatory
Loan Sales. In addition to all other rights of Sallie Mae described herein
(including, but not limited to, the rights more fully described in Sections 8
and 9 hereof), in the event of any payment Default by the Borrower under
Section 9.B hereof, the Borrower hereby agrees to promptly sell Insured Loans
to ECFC in an amount sufficient to cover such payment Default.  Any such loan sale shall be made in accordance
with the terms of the ExportSS Agreement.

 

SECTION 4. CONDITIONS PRECEDENT.

 

The
obligation of Sallie Mae to enter into this Agreement, and to make any Advance
hereunder, shall be subject to compliance, in all material respects, with each
of the following conditions:

 

(1) All
legal matters incident to the making of this Agreement or the making of such
Advance shall be approved by counsel to Sallie Mae.

 

(2) Sallie
Mae shall have received, in form and substance satisfactory to Sallie Mae and
its counsel, the following:

 

(a)
A Note, in the form of Annex A hereto.

 

(b)
A certificate of the secretary or other appropriate officer of the Borrower
substantially in the form of Annex B hereto.

 

(c)
Assignment of the Security in the form of Annex D-2 hereto.

 

(d)
The Financials referred to in Section 2.A hereof.

 

8

 

(e)
With respect to any Insured Loans included in the Security, counterparts of one
or more financing statements (UCC-1), signed (if required) by the Borrower and
the Trustee, in such number as Sallie Mae shall request, in which the Borrower
and the Trustee are designated as “Debtor” and Sallie Mae as “Secured Party,”
covering the collateral more fully described on Annex E hereto.

 

(f)
An opinion of counsel to the Borrower, substantially in the form of Annex G
hereto.

 

(g)
If Sallie Mae is not the sole Servicer of the Insured Loans, a Custodian Agreement
among Sallie Mae, the Servicer, and the Borrower, that provides for the
Servicer to hold the Insured Loans and all documentation relating to the
Insured Loans as custodian and agent for Sallie Mae.

 

SECTION 5. COMMITMENT FEE

 

[INTENTIONALLY
OMITTED] 

 

SECTION 6. MANNER OF BORROWING

 

Sallie
Mae, in its capacity as Servicer of the Insured Loans, will send a Request
Register to the Borrower at least one Business Day prior to the date the funds
for the individual Insured Loan disbursements shown on the Request Register are
scheduled to be received by the school. The Borrower hereby authorizes Sallie
Mae to make an Advance to the Borrower in the amount shown on such Request
Register. Sallie Mae agrees, subject to the remaining terms of this Agreement,
to make such Advance to the Borrower, in most cases (except where the school’s
process requires an alternate schedule) no later than 2:00 p.m. Central time at
least one Business Day prior to the date such Insured Loan disbursements are
scheduled to be received by the school.

 

Additionally,
if Sallie Mae is not the sole Servicer of the Insured Loans, then the Borrower
shall also be required to submit to Sallie Mae, on the same day that the
Borrower receives the Request Register, a Compliance Certificate in the form of
Annex C hereto, dated as of the date of such Advance, that discloses that the
Security is in compliance with Section 8.A.(2) hereof.

 

SECTION 7. PARTICULAR COVENANTS OF THE BORROWER

 

From
the date hereof and until the Maturity Date and the performance of all other
obligations of the Borrower under this Agreement, the Borrower agrees that:

 

A.
Investment of Proceeds. Advances made hereunder shall only be used for
the purpose of funding originations of Insured Loans under the ExportSS
Agreement.

 

9

 

B.
Financial Statements and Other Information. The Borrower shall furnish
to Sallie Mae:

 

(1)           As soon as possible and in no event
more than ninety (90) days after the end of each fiscal year of the Borrower,
Financials as at the end of and for such year.

 

(2)           As soon as possible and in no event
more than forty-five (45) days after the end of each quarterly accounting
period of the Borrower, Financials as at the end of and for such period.

 

(3)           Promptly upon Sallie Mae’s request,
such other information regarding the Borrower’s financial condition and
affairs, and regarding the Security or Insured Loans owned by the Borrower, as
Sallie Mae may reasonably request.

 

(4)           Promptly after the commencement
thereof, notice of any action, suit or proceeding before any court or
governmental department, commission, board, bureau, agency or instrumentality,
domestic or foreign, involving the Borrower that might have a material adverse
effect upon the financial condition of the Borrower or on the Borrower’s
ability to perform its obligations under this Agreement.

 

(5)           Within five (5) business days
following the effective date of any change in name or address of the Borrower,
or the name or address of the Trustee, written notice of such change to the
addresses provided in Section 10.

 

C.   Maintenance
of Existence; Conduct of Operations. The Borrower will preserve and
maintain its corporate existence and all of its rights, privileges, and
franchises necessary or desirable in the normal conduct of its operations, and
the Borrower will conduct its operations in an efficient and regular manner.

 

D.   Compliance
with Applicable Laws. The Borrower will comply with the requirements of all
applicable laws, rules, regulations, and orders of any governmental authority, a
breach of which would materially adversely affect the operations or credit of
the Borrower, except where contested in good faith and proper proceedings.

 

E.   Compliance
Certificate. If any of the Insured Loans are originated or serviced by a
Servicer other than Sallie Mae, then within ten (10) days after the end of each
calendar quarter, the Borrower shall furnish to Sallie Mae a Compliance
Certificate, completed and executed as of the last day of such quarter by an
authorized official of the Borrower; provided,
however, that if an Advance has been disbursed within thirty (30)
days prior to the end of such quarter, this requirement shall be waived with
respect to such period.

 

F.   Collateral
Listing. If any of the Insured Loans are originated or serviced by a Servicer
other than Sallie Mae, then on the date this Agreement is executed by the
parties hereto and within forty-five (45) days after the end of each calendar
year, the Borrower shall provide Sallie Mae with a current listing of the
Insured Loans included in the Security showing (i) the outstanding principal
balance of and accrued interest on each Insured Loan, and (ii) a current delinquency
aging of the Insured Loans included in the Security.

 

10

 

G.   Contact
With Student Borrowers. So long as any Insured Loan shall be included in
the Security, at least once within each twelve month period the Borrower shall
be in contact with the respective student borrower.  Any of the following shall be deemed to
constitute contact: (i) verification of current address and receipt of an
acknowledgement of liability; (ii) receipt of a payment of principal and/or
interest, (iii) disbursement of an additional student loan; or (iv) a status
verification conducted by an Eligible Insurer.

 

H.   Servicer
Operations Report. If any of the Insured Loans are originated or serviced
by a Servicer other than Sallie Mae, then Borrower shall furnish to Sallie Mae,
within fifteen (15) days after the end of each calendar quarter, a written
report prepared by the Servicer in the form of Annex F hereto showing the
claims and delinquency status of Insured Loans included in the Security.

 

I.   Updated
Secretary’s Certificate. Within ten (10) days of the addition of any
individual to the authorized signers listed on the Borrower’s secretary’s
certificate delivered pursuant to Section 4.A(2)(b) hereof, the Borrower shall
furnish to Sallie Mae an updated secretary’s certificate, providing the name,
title, and sample signature of the additional person(s) authorized to execute
documents on the Borrower’s behalf.

 

J.   Sale
of Insured Loans. Borrower and the Trustee acknowledge that, under and
pursuant to the terms of the ExportSS Agreement, all Insured Loans that are
financed, in whole or in part, with the proceeds of any
Advance, are required to be offered for sale to ECFC, irrespective of where or
by whom such loans are originated or serviced.

 

K.   Sovereign
Immunity. The Borrower waives whatever rights it may have to claim against
Sallie Mae immunity afforded to a sovereign entity from suit and legal process (whether in aid of jurisdiction, prejudgment attachment, or
execution on a judgment) to the fullest extent permitted by law.

 

L.   Other
Requirements. Within ten (10) days following a written request
from Sallie Mae, the Borrower will furnish Sallie Mae with:

 

(1) such
opinions of counsel to the Borrower as Sallie Mae may reasonably request as to (a)
the status of Sallie Mae’s security interest in the Insured Loans that have
been assigned and transferred to Sallie Mae as Security for the Advances
hereunder as a prior first lien on such Insured Loans; and (b) such other
matters incident to the transactions hereby contemplated as Sallie Mae or its
counsel may reasonably request; and

 

(2) such
other documents, agreements, and information as Sallie Mae may reasonably request,
including additional Assignments.

 

SECTION 8. SECURITY

 

A.            (1) The Security for the Advances
and all other Obligations of the Borrower to Sallie Mae shall consist of all
FFELP Loans from time to time beneficially owned by the Borrower and legally
owned by the Trustee as may from time to time be pledged to Sallie

 

11

 

Mae, and all other property
as set forth and defined as Security in the Assignment. Unless otherwise agreed
by Sallie Mae in writing, every FFELP Loan that is legally or beneficially
owned by the Borrower (or legally owned by the Trustee) shall be pledged to
Sallie Mae and included in the Security at all times prior to sale to ECFC.

 

(2)           The aggregate unpaid principal
balance of Eligible Loans included in the Security divided by 1.0 shall at all
times be equal to or exceed the amount of the unpaid principal balance of the
Note. In the event all or any portion of the Security shall mature, shall be
paid or retired, or shall otherwise be reduced in amount prior to the Maturity
Date, the Borrower shall promptly, and in any event upon the demand of Sallie
Mae within two days of a request therefor, pledge to Sallie Mae (or cause the
Trustee to pledge to Sallie Mae), and grant to Sallie Mae (or cause the Trustee
to grant to Sallie Mae) a security interest in, such additional Security, in
such amounts as may be necessary or as may be requested by Sallie Mae, so that
the amount of the Security shall be equal to or greater than the amount
initially required by this Section 8.A(2), provided,
however, that in the
event additional Eligible Loans are not available to the Borrower or the
Trustee for inclusion in the Security, the Borrower shall pay to Sallie Mae for
application to the principal of the Advance an amount sufficient to reduce the
principal balance of the Advance such that the percentage of Eligible Loans
pledged shall be at least equal to the amount required under this Section
8.A(2). An Insured Loan shall become ineligible for purposes of the computation
made above at the time it becomes overdue in respect of the payment of
principal or interest for more than thirty (30) days. Such Insured Loans,
however, shall continue to be pledged and assigned to Sallie Mae and shall be
included within the Security for the Advance.

 

B.
The following provisions shall apply to the Security and the holding,
servicing, administration, and disposition thereof:

 

(1)           If any of the Insured Loans are
originated or serviced by a Servicer other than Sallie Mae, then (a) the
Insured Loans forming the Security under the Agreement shall be physically
segregated from all other property of the Borrower and marked or otherwise designated
to disclose the security interest of Sallie Mae therein, and (b) the Insured
Loans that are financed, in whole or in part, with the proceeds of any Advance
shall be either (i) physically segregated from the Insured Loans of the
Borrower that are not so financed, or (ii) marked or otherwise designated to
the reasonable satisfaction of Sallie Mae as having been financed with the
proceeds of an Advance.  In the event the
Student Notes relating to the Insured Loans are in the form of master
promissory notes, the Borrower shall provide for the delivery to Sallie Mae of certified
copies of such master promissory notes if such copies are needed to prove the
existence of (or otherwise to assist in the collection of) such Insured Loans.

 

(2)           The Borrower shall, at its own
expense, (or shall cause the Servicer to) administer, service, and collect all
Insured Loans from time to time included in the Security, and maintain
appropriate books and records in respect thereof, whether or not Sallie Mae
shall exercise any of its rights hereunder (and the foregoing requirement shall
be deemed satisfied if Sallie Mae is the sole Servicer for the Loans); provided, however, that Sallie Mae or its designated
agent, upon ten (10) days’ prior written notice to the Borrower, may assume, at
the expense of the Borrower, the administration, servicing, and collection of
the Insured Loans included in the Security if such actions are necessary to
preserve the value of the Security and Sallie Mae’s rights therein. With the
prior written approval of Sallie Mae, which may be

 

12

 

withheld in Sallie Mae’s
sole discretion, the Borrower and the Trustee may delegate to another, upon
terms satisfactory to Sallie Mae, the functions of administering, servicing,
and collecting such Insured Loans, but Borrower acknowledges that in no event
will Sallie Mae grant such approval for the Borrower and the Trustee to
delegate such servicing functions to any entity (other than an affiliate of
Sallie Mae) with respect to the Insured Loans that are part of the Security
that were financed with the proceeds of any Advance.

 

(3)   Without
the prior written consent of Sallie Mae, the Borrower shall not maintain any of
its books and records with respect to Insured Loans included in the Security away
from the Borrower’s premises in Baltimore, MD, or at Sallie Mae’s premises,
except in the event of an emergency, which shall include fire and flood. In the
event of an emergency, Borrower shall notify Sallie Mae as soon as possible.

 

(4)   The Borrower shall at all times prior to the
Maturity Date maintain Eligible Loans in the Security in an amount equal to or
exceeding the amount specified in Section 8.A.(2) hereof. An Insured Loan shall
become ineligible for purposes of the above computation at the time it becomes
overdue in respect of the payment of principal or interest for more than thirty
(30) days. Such Insured Loans, however, shall continue to be pledged and
assigned to Sallie Mae and shall be included within the Security.

 

(5)   Without
the prior written consent of Sallie Mae, neither the Borrower nor the Trustee
shall file or permit to be filed in any jurisdiction any financing statement or
like instrument with respect to the Security or any part thereof in which
Sallie Mae is not named as the sole secured party.

 

(6)   Sallie
Mae reserves the right, at any time, to file in appropriate offices the financing
statements referred to in Section 4(2)(e) hereof, and the Borrower and the
Trustee each hereby appoints Sallie Mae its attomey-in-fact to execute in the
Borrower’s and the Trustee’s name all such financing statements, as well as
amendments, renewals, and modifications thereof, and to file such documents in
the appropriate offices.

 

(7)   The
Borrower and the Trustee shall, upon the demand of Sallie Mae,

 

(a)   give,
execute, deliver, file, and/or record any notice, statement, instrument, document,
agreement, or other papers that may be necessary or desirable in the sole
judgment of Sallie Mae, in order to create, preserve, perfect, or validate any security
interest granted pursuant to this Agreement or to enable Sallie Mae to exercise
and enforce its rights hereunder with respect to such security interest; and

 

(b)   at
any reasonable time and from time to time, permit Sallie Mae or any agents or
representatives to examine and make copies of the records and books of account
related to the Security and the transactions contemplated by this Agreement, to
visit the Borrower’s and the Trustee’s properties and to discuss the Borrower’s
and the Trustee’s affairs, finances, and accounts with any of the Borrower’s or
the Trustee’s officers and independent accountants and to discuss the Borrower’s
student loan program and the Insured Loans included in the Security with any
Eligible Insurer.

 

13

 

(8)   From
time to time upon the demand of Sallie Mae, the Borrower and the Trustee shall:

 

(a)   endorse
the Student Notes contained In the Security and deliver the same to Sallie Mae
or its Agent for safekeeping and/or prepare and furnish to Sallie Mae such
instruments of assignment and transfer in such form and substance as may be specified
by Sallie Mae in its demand;

 

(b)   keep
and otherwise maintain the Borrower’s and the Trustee’s books and records
relating to the Insured Loans and Student Notes included in the Security in such
manner as Sallie Mae may require;

 

(c)   prepare
and furnish to Sallie Mae such records, lists, schedules, and other information
relating to the Insured Loans and Student Notes included in the Security,
including such information as may be contained in computerized databases
maintained by the Borrower or its agents, as may be requested by Sallie Mae
from time to time; and

 

(d)   take
such additional actions as may be necessary or useful to facilitate the administration,
servicing, and collection of the Insured Loans included in the Security in the
event Sallie Mae exercises its rights under Section 8.B(2) hereof.

 

(9)   Sallie
Mae may, in its discretion (but shall not be obliged to) with the consent of
the Borrower and the Trustee (which consent may not unreasonably be withheld)
in its name or in the name of the Borrower and the Trustee or otherwise,
demand, sue for, collect, or receive any money or property at any time
receivable on account of or in exchange for any of the Security, and Sallie Mae
may make any compromise or settlement deemed desirable with respect to any of
the Security and may extend the time of payment, arrange for payment in
installments, otherwise modify the terms of, or release any of the Security,
without thereby incurring responsibility to, or discharging or otherwise
affecting any liability of, the Borrower or the Trustee. The Borrower and the Trustee
hereby authorize Sallie Mae, either in its own name or in the name of the
Borrower or the Trustee, to file all claims for reimbursement under the
certificate of insurance assigned to Sallie Mae hereunder and to receive the
proceeds therefrom.

 

(10)   Upon
Default in the payment when due of any principal of or interest on any Advance
or other Obligation, including any liability arising under Sections 3.E and 9
hereof,

 

(a)   Sallie
Mae shall have the rights and remedies with respect to the Security of a secured
party under the Uniform Commercial Code as in effect at the time of the Default;
and

 

(b)   with
respect to the Security, upon ten (10) days’ prior written notice to the Borrower
and the Trustee, Sallie Mae may sell or cause to be sold, at such time or places
as Sallie Mae in its discretion shall decide, and for cash or on credit or for the
future delivery (without thereby assuming any credit risk), all or any of the Security,
including the Borrower’s and the Trustee’s rights and interest in the

 

14

 

Student
Notes forming a part of the Security, at public or private sale (including,
without limitation, a sale to ECFC pursuant to the terms of the ExportSS
Agreement), without demand of performance or notice of intention to sell or of
time or place of sale (except such notice as is required above or by applicable
statute that cannot be waived), and Sallie Mae or anyone else may be the
purchaser of any or all of the Security so sold and thereafter hold the same
absolutely free from any claim or right of whatsoever kind of the Borrower and
the Trustee, any such demand and notice of rights being hereby expressly waived
and released by the Borrower and the Trustee. The proceeds of each such sale
under this Section 8.B(10) shall be applied in accordance with Section 8.B(11)
hereof. If the proceeds of the sale, collection, or other realization of or
upon the Security are insufficient to cover the expenses of such realization
and the payment in full of the Obligations, the Borrower shall remain liable
for any deficiency.

 

(11)   Unless
Sallie Mae and the Borrower otherwise agree, Sallie Mae shall apply all amounts
received by it in respect of the Security under Section 8.B(9) or Section
8.B(10), as follows: first, to
pay the expenses of Sallie Mae in connection with collecting such amounts; second, to the payment of the Obligations,
first to interest, second to principal, and third to any remaining Obligations;
and third, any balance remaining
after the payment in full of the Obligations shall be released to the Borrower,
or its successor and assigns.

 

(12)   If
Sallie Mae so requests, whether or not a Default exists, the Borrower and the
Trustee shall forthwith pay to Sallie Mae at its offices all amounts received
by the Borrower or the Trustee upon or in respect of any Security,
appropriately advising Sallie Mae as to the source of such funds.

 

SECTION 9. DEFAULTS; SUSPENSION OF COMMITMENT

 

Defaults

 

If
any of the following defaults shall occur, namely:

 

A.   Any
representation or warranty in this Agreement or in any certificate or writing
furnished to Sallie Mae pursuant hereto shall prove to have been incorrect in
any material respect or shall be breached in any material respect; or

 

B.   Default
in the payment when due of any principal of or interest on any Advance or other
Obligation, including any payment that may be required under Section 3.E hereof;
or

 

C.   The
Borrower or the Trustee shall fail to perform any of the covenants or undertakings
in Section 7 of this Agreement or any other provision of this Agreement; or

 

D.   The
Borrower or the Trustee shall (i) apply for or consent to the appointment of a
conservator, receiver, trustee, liquidator, or the like for itself or its
property; (ii) be unable, or admit in writing its inability, to pay its debts
as they mature, (iii) make a general assignment for the benefit of creditors;
(iv) be adjudicated as bankrupt or insolvent; (v) if the Borrower or the

 

15

 

Trustee is a financial
institution, be seized, taken over, or otherwise subjected to the
decision-making control of or by its regulatory authorities; or (vi) file a
voluntary petition in bankruptcy or a petition or answer seeking reorganization
or an arrangement with creditors or to take advantage of any insolvency law or
an answer admitting the material allegations of a petition filed against it in
any bankruptcy, reorganization, or insolvency proceedings, or corporate action
shall be taken by it for the purpose of effecting any of the foregoing; or

 

E.   An
order, judgment, or decree shall be entered without the application, approval,
or consent of the Borrower or the Trustee by any court or governmental agency
of competent jurisdiction, approving a petition seeking reorganization of the
Borrower or the Trustee or appointing a conservator, receiver, trustee,
liquidator, or the like for the Borrower or the Trustee or for all or a
substantial part of either of their assets and such order, judgment, or decree
shall continue unstayed or in effect for any period of thirty (30) consecutive
days, or an involuntary petition shall have been filed against the Borrower or
the Trustee in bankruptcy or seeking reorganization under the Bankruptcy Act
and the same shall not have been dismissed within sixty (60) days; or

 

F.   Sallie
Mae’s rights and prospects of repayment of any current or future Advances
hereunder are, in Sallie Mae’s reasonable judgment, in any way prejudiced or
rendered insecure

 

THEN,
in any such case, Sallie Mae may by written notice to the Borrower
and the Trustee terminate the Commitment and/or, if any Advance or Advances are
then outstanding, declare the principal of and interest on any such Advance or
Advances to be forthwith due and payable, whereupon the same shall become
forthwith due and payable, without protest, presentment, or demand, all of
which are expressly waived by the Borrower and the Trustee.

 

Suspension
of Commitment

 

If,
in the absence of a Default, Sallie Mae in its reasonable judgment determines
that there has occurred a material adverse change in the financial condition of
the Borrower, the Trustee, or with respect to the management of the Borrower or
the Trustee, or in the Borrower’s ability to administer its student loan
program, or in the quality of the Security, with the result that Sallie Mae’s
rights or prospects of repayment of any current or future Advance are
prejudiced, Sallie Mae, by written notice to the Borrower and the Trustee, may
suspend the Commitment and Sallie Mae shall not have the obligation to make
additional Advances until Sallie Mae in its reasonable judgment is satisfied
that the condition(s) that caused the determination has (have) been remedied.

 

SECTION 10. NOTICES

 

All
notices, requests, demands, and other communications herein shall be in
writing, and, except as otherwise specifically provided in this Agreement,
shall be deemed to have been duly given if delivered or mailed, first class,
postage prepaid, to the parties at the following addresses (or at such other
address for a party as shall be specified by like notice):

 

A.   If to
Sallie Mae, at 12061 Bluemont Way, Reston, VA 20190, Attention:

 

16

 

Financing Administration and
Loan Documentation, with copies to Senior Vice President, Financial Institution
Sales, Sallie Mae, Inc., 11100 USA Parkway, Fishers, IN 46037. Copies of
notices of name or address changes of the Borrower shall also be sent to Andrew
G. Wachtel, Sallie Mae, Inc., 12061 Bluemont Way, Reston, VA 20190; Fax Number:
703-984-5979.

 

B.
 If to the Borrower, at 1001 Fleet
Street, Baltimore, MD 21202, Attention: Robert Zentz, General Counsel.

 

C.
 If to the Trustee, at 7077 Bonneval
Road, Suite 400, Jacksonville, FL 32216, Attention: Tricia Heintz, Vice
President.

 

SECTION 11. MISCELLANEOUS

 

A.   Waivers, Etc. No failure on the part of Sallie Mae to
exercise, and no delay in exercising, any right hereunder will operate as a
waiver thereof; nor will any single or partial exercise or waiver of any right
hereunder preclude any other or further exercise thereof or the exercise of any
other right. The remedies herein provided are cumulative and not exclusive of any
remedies provided by law.

 

B.   Expenses.
The Borrower will pay:

 

(1)  all taxes, if any, upon documents or
transactions pursuant to this Agreement; and

 

(2)  costs of collection (including without
limitation all reasonable counsel fees) in the event of any Default hereunder.

 

C.   Counterparts.
This Agreement may be executed in any number of counterparts, all of which
taken together will constitute one agreement, and any of the parties hereto may
execute this Agreement by signing any such counterpart.

 

D.   Law
Governing. This Agreement and the Note are being delivered in and shall be
construed in accordance with and governed by the laws of the Commonwealth of Virginia,
without giving effect to any choice of law or conflict of law provisions or
principles (whether of the Commonwealth of Virginia or any other jurisdiction)
that would cause the application of any laws of any jurisdiction other than the
Commonwealth of Virginia. All parties hereby irrevocably and unconditionally
submit to the jurisdiction of any state court sitting in Fairfax County,
Virginia, and the Federal District Court sitting in the City of Alexandria, Virginia,
over any suit, action, or proceeding arising out of or relating to this
Agreement and the Note. Each party hereby irrevocably and unconditionally
waives any objection to the laying of venue in any such court and any claim
that such court is an inconvenient forum.

 

E.   Mandatory
Prepayment and Termination of Commitment. If for any reason the ExportSS
Agreement (or ECFC’s obligation to purchase Insured Loans thereunder) is
terminated by either party thereto prior to the Maturity Date of this Financing
Agreement, then the Borrower shall, within three (3) Business Days of such
termination, pay all Obligations outstanding under

 

17

 

this Agreement, and,
notwithstanding any other provisions contained herein to the contrary, Sallie
Mae’s Commitment to make any further Advances hereunder shall be terminated.

 

F.   Right
to Terminate. Anything contained in this Agreement to the contrary notwithstanding,
at anytime prior to the Maturity Date, either party hereto may terminate this Agreement
upon sixty (60) days’ prior written notice to the other party only in the event
that such party is permitted to terminate the ExportSS Agreement at such time.
The Borrower shall, on the effective date of such termination, pay all
Obligations outstanding under this Agreement, and Sallie Mae’s Commitment to
make any further Advances hereunder shall be terminated.

 

G.   Termination
of Agreement. Sallie Mae (or the Borrower with respect to subparagraph (a)
of this paragraph) may, but shall not be obligated to, terminate this Agreement
upon thirty (30) days’ prior written notice to the other parties if:

 

(a)
for any reason the Secretary alleges in writing (either formally or informally)
that: (i) Sallie Mae’s providing financing to the Borrower under the terms of
this Agreement, or (ii) all or any part of any other agreement, contract,
indenture, or other instrument among the Borrower, the Trustee, and Sallie Mae
or among the Borrower, the Trustee, and ECFC, is in violation of the Act
(including, without limitation, the “prohibited inducements” guidelines issued
by the Secretary), or (iii) Sallie Mae should be re-characterized as the “lender”
of the Insured Loans; or

 

(b)
any offset, holder, or other fee is imposed on Sallie Mae with respect to
Insured Loans beneficially owned by the Borrower and legally owned by the
Trustee that are financed by Sallie Mae, if such fee is imposed for the time
period that the Borrower or the Trustee still owned the Insured Loans.

 

The Borrower shall, on the
effective date of such termination, pay all Obligations outstanding under this
Agreement, and, notwithstanding any other provisions contained herein to the
contrary, Sallie Mae’s Commitment to make any further Advances hereunder shall
be terminated.

 

H.   Assignment.
This Agreement shall be assignable by Sallie Mae. Sallie Mae agrees to give the
Borrower and the Trustee at least sixty (60) days’ prior written notice of an
assignment of the duties, rights, and obligations of Sallie Mae under the
Agreement. This Agreement is not assignable by the Borrower or the Trustee,
except (i) in the circumstance of the replacement or resignation of the Trustee
and the appointment of a substitute trustee for the Borrower, or (ii) in the
circumstance where the Borrower assigns or transfers its rights under this
Agreement to a non-profit entity in compliance with the provisions and
limitations of the Higher Education Act; provided,
however, that following any such assignment, the Borrower will
remain liable for all obligations of the Borrower that are set forth in this
Agreement.

 

18

 

IN
WITNESS WHEREOF, the parties hereto have
caused this Agreement to be duly executed as of the date and year first above written.

 

 

	
  SALLIE
  MAE, INC.

  	
  WALDEN
  UNIVERSITY, INC.

  
	
   

  	
   

  
	
  By:

  	
  /s/ Jerry Maher

  	
   

  	
  By:

  	
  /s/ Richard Patro

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Jerry Maher

  	
   

  	
  Name: 

  	
  Richard Patro

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Senior Vice President

  	
   

  	
  Title:

  	
  CFO, Walden University

  	
   

  
										

 

WELLS FARGO BANK, NATIONAL

ASSOCIATION, solely in its capacity as 

Eligible Lender Trustee for Walden University, 

Inc.

 

	
  By:

  	
  /s/ Tricia Heintz

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Name:

  	
  Tricia Heintz

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Title:

  	
  Vice President

  	
   

  	
   

  
						

 

19

 

ANNEX A

 

PROMISSORY NOTE

 

	
  Reston,
  Virginia 

  
	
  $100,000,000

  	
  July
  1, 2006

  

 

FOR VALUE RECEIVED, the
undersigned (the “Borrower”) hereby promises to pay to the order of Sallie Mae,
Inc. (“Sallie Mae”), at the offices of its designated agent, on the later of
(i) May 31, 2009 or (ii) the date of the last scheduled sale of Eligible Loans
under the ExportSS® Agreement (the “Maturity Date”), in lawful money of the
United States, the principal sum of One Hundred Million and 00/100 Dollars
($100,000,000.00), or such lesser principal sum as shall equal the balance
outstanding of the Advances made by Sallie Mae to the Borrower from time to
time under a Revolving Financing Agreement dated July 1, 2006 (the “Financing
Agreement”), and to pay interest on the aggregate principal balance of the
Advances outstanding at the end of each day during the period commencing on the
date hereof and ending on the date said principal balance outstanding is paid
in full at a rate per annum, to the extent permitted by law, that shall be
determined as to each such day by adding a specified percentage (the “Margin”)
to the weighted average of the bond equivalent rates of the quotes of the
3-month commercial paper (financial) rates in effect for each of the days in
such quarter as reported by the Federal Reserve in Publication H-15 (or its
successor) for such 3-rnonth period (computed on the basis of actual days
elapsed and a year of 365 or 366 days, as appropriate). The Margin shall be
fifty one-hundredths percent (0.50%) per annum from the date of this Note until
all Obligations are paid in full.

 

For
purposes hereof, the bond equivalent rates of the quotes of the 3-month
commercial paper (financial) rates shall be determined by (A) multiplying the
3-month commercial paper (financial) rate by the actual number of days in the
year (365 ordinarily, but 366 if February 29 falls within the year), and then
dividing the result in (A) by (B) the result of the following two calculations:
(i) multiplying the 3-month commercial paper (financial) rate by 90, and (ii)
subtracting the product determined in clause (i) from 360.  The resulting rate shall then be rounded to
five (5) decimal places. For any day that is a Saturday, Sunday, or business
holiday, the rate shall be determined by using the rate on the immediately
preceding Business Day.

 

Interest
hereunder shall be accrued and shall be due and payable on the first Business
Day following the last day of each month, except that the final interest
payment hereunder shall be due and payable on the same day as the principal
hereunder.

 

All
payments of principal and interest hereunder shall be made in lawful money of
the United States in immediately available funds to the designated agent of
Sallie Mae. Interest hereunder shall be calculated on the basis of actual days
elapsed and a year of 365 days or 366 days, as applicable. If any principal of
or interest on the Advances falls due on a Saturday, Sunday, or legal holiday
at the place of payment, then such due date shall be extended to the next
succeeding full Business Day at such place, and interest, in the case of a
principal payment, shall be payable in respect of such extension.

 

This
Note evidences Advances made pursuant to the above-mentioned Financing

 

1

 

Agreement between the
Borrower and Sallie Mae, providing for the Advances, the acceleration of the
maturity of such Advances, and for the prepayment thereof, all on the terms set
forth in said Financing Agreement. Unless otherwise defined, capitalized terms
used herein shall have the meanings ascribed to them in the Financing
Agreement.

 

IN
WITNESS WHEREOF, the Borrower has caused this Note to be executed by its duly
authorized representative.

 

 

	
   

  	
  WALDEN
  UNIVERSITY, INC.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  
	
   

  	
  Name:

  	
   

  
	
   

  	
   

  
	
   

  	
  Title:

  	
   

  
	
   

  	
   

  
	
  [Corporate Seal]

  	
   

  
					

 

2

 

ANNEX B

 

BORROWER’S 

SECRETARY’S
CERTIFICATE

 

I,                                                                            , Secretary of                                                                       ,
a                                  corporation organized under the laws of
the State of                                      (the
“Borrower”), hereby certify to Sallie Mae, Inc. that:

 

1.   Attached
hereto as Exhibits 1 and 2 are true copies of the By-Laws and Articles of
Incorporation of the Borrower as in effect on the date hereof.

 

2.   Attached
hereto as Exhibit 3 is a true copy of certain resolutions duly adopted by the        [Committee]
of the Board of Directors of the Borrower at a meeting duly called and held on                    ,
at which a quorum was present and acting throughout.  Said resolutions are still in full force and
effect and have not been amended, superseded, or revoked.

 

3.   The
persons named below are at the date hereof the duly elected, qualified, and acting
officers of the Borrower holding the offices indicated, and the signature
following each name is the genuine signature of the person named:

 

	
  Name

  	
   

  	
  Title

  	
   

  	
  Signature

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  

 

WITNESS
my hand and the seal of the Borrower this      day
of                         ,
20    .

 

 

	
                                                             

  	
  ,
  Secretary

  
	
  (SEAL)

  	
   

  

 

1

 

EXHIBIT 3

to 

SECRETARY’S CERTIFICATE

 

 

RESOLVED, that [either] the                            [or/and]
                                    
of                                       
be and each of them, acting singly, hereby is authorized, in the name and on
behalf of
                                             ,
this                               day
of     , 20   , to execute a Revolving
Financing Agreement with Sallie Mae, Inc. (“Sallie Mae”) in the form that has
been submitted to this meeting and that shall be marked by the Secretary for
identification and filed among the records of this Corporation.

 

FURTHER
RESOLVED, that [either] the                            [or/and]
                       
of                     
be and each of them, acting singly, hereby is authorized in the name and on behalf of
                         ,
from time to. time to borrow from Sallie Mae up to an aggregate amount of $               and
to sign and deliver promissory notes
of             evidencing
such borrowing and assignments and other instruments relative to collateral
security therefor, all as provided in said Revolving Financing Agreement.

 

FURTHER
RESOLVED, that all above-named officers of                    
be and they hereby are each authorized on behalf of            
to execute all such  instruments
and to perform all such other acts as may be appropriate for the purpose of
carrying out the foregoing resolutions and effecting said Revolving Financing
Agreement.

 

 

	
   

  	
  Certified as True and
  Correct.

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Secretary

  
	
   

  	
   

  
	
  [Corporate Seal]

  	
   

  

 

1

 

ANNEX B-1

 

TRUSTEE’S 

SECRETARY’S CERTIFICATE

 

I,
                                           
, Secretary of
                                                  
(acting solely in its capacity as eligible lender trustee for [INSERT
BORROWER]), a corporation organized under the laws of the State of
                                        
(in such capacity, the “Trustee”), hereby certify to Sallie Mae, Inc. that:

 

1.   Attached
hereto as Exhibits 1 and 2 are true copies of the By-Laws and Articles of
Incorporation of the Trustee as in effect on the date hereof.

 

2.   Attached
hereto as Exhibit 3 is a true copy of certain resolutions duly adopted by the
                    
[Committee] of the Board of Directors of the Trustee at a meeting duly called
and held on
                                
, at which a quorum was present
and acting throughout. Said resolutions are still in full force and effect and
have not been amended, superseded, or revoked.

 

3.   The
persons named below are at the date hereof the duly elected, qualified, and acting
officers of the Trustee holding the offices indicated, and the signature
following each name is the genuine signature of the person named:

 

	
  Name

  	
   

  	
  Title

  	
   

  	
  Signature

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  

 

WITNESS my hand and the
seal of theTrustee this        day of
                        
, 20    .

 

 

	
                                                             

  	
  ,
  Secretary

  
	
  (SEAL)

  	
   

  

 

1

 

EXHIBIT 3

to 

SECRETARY’S CERTIFICATE

 

RESOLVED, that [either] the
                                               
[or/and]
                                     
of
                                     
be and each of them, acting singly, hereby is authorized, in the name and on
behalf of
                                          
(acting solely in its capacity as eligible lender trustee for [INSERT
BORROWER]) (in such capacity, “Trustee”), this day
           of                           
, 20    , to execute a Revolving Financing Agreement with
Sallie Mae, Inc. (“Sallie Mae”) in the form that has been submitted to this
meeting and that shall be marked by the Secretary for identification and filed
among the records of this Corporation.

 

FURTHER RESOLVED,
that [either] the                                            
[or/and]
                                                          
of
                                  
be and each of them, acting singly, hereby
is authorized in the name and on behalf of the Trustee, from time to time to
sign and deliver assignments and other instruments relating to granting a
security interest in the student loans referenced in the Revolving Financing
Agreement, all as provided in said Revolving Financing Agreement.

 

FURTHER RESOLVED, that all above-named
officers of the Trustee be and they hereby are each authorized on behalf of the
Trustee to execute all such instruments and to perform all such other acts as
may be appropriate for the purpose of carrying out the foregoing resolutions and
effecting said Revolving Financing Agreement.

 

 

	
   

  	
  Certified as True and
  Correct.

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Secretary

  
	
   

  	
   

  
	
  [Corporate Seal]

  	
   

  

 

1

 

ANNEX C

 

BORROWER 

COMPLIANCE CERTIFICATE 

(as
of                                      , 20    )

 

The undersigned,                                                        
, hereby certifies to
Sallie Mae, Inc. (“Sallie Mae”) that on and as of the date hereof, the
information below set out is correct and has been prepared in accordance with the
applicable provisions of a certain Revolving Financing Agreement dated
                                
(the “Agreement”) among [BORROWER], [TRUSTEE], and Sallie Mae:

 

COLLATERAL
COMPLIANCE:

 

A. Principal Balance of Advances outstanding:
$                                                   .

 

B. Aggregate unpaid principal balance of
Eligible Loans owned by Borrower and pledged to Sallie Mae as of the date
hereof: $                                                 .

 

	
  C.

  	
  B

  	
   

  	
  =

  	
  $

  	
   

  	
  .

  
	
   

  	
  1.0

  	
   

  	
   

  	
   

  

 

Amount of “C” must equal or exceed amount of “A”.

 

Amount of “B”
excludes $
                                                     
in Insured Loans in
respect of which the payment of principal or interest is at the time overdue
for more than thirty (30) days. 

 

Unless otherwise defined, all terms herein are used as defined in the
Agreement.

 

IN
WITNESS WHEREOF, the undersigned has
caused this certificate to be signed by an authorized officer this
                  
day of
                  
, 20       .

 

 

	
  [BORROWER]

  	
   

  	
  Please forward certificate
  to:

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  Sallie Mae, Inc. 

  
	
   

  	
   

  	
  1002 Arthur Drive

  
	
  Name:

  	
   

  	
   

  	
  Lynn Haven, FL 32444

  
	
   

  	
   

  	
  Attention:

  	
  Compliance Analyst

  
	
  Title:

  	
   

  	
   

  	
   

  	
  Financial Reconciliation

  
							

 

 

ANNEX D-1

 

[INTENTIONALLY OMITTED]

 

 

ANNEX D-2

 

ASSIGNMENT AND SECURITY AGREEMENT

 

THIS
ASSIGNMENT AND SECURITY AGREEMENT dated as of July 1, 2006, is made pursuant to
a Revolving Financing Agreement dated July 1, 2006 (the “Agreement”) among
Walden University, Inc. (the “Borrower”), Sallie Mae, Inc. (“Sallie Mae”), and
Wells Fargo Bank, National Association, solely in its capacity as Trustee for
the Borrower under the terms of that certain Eligible Lender Trust Agreement
dated as of June 15, 2006, between the Borrower and the undersigned (the “Trustee”).
Terms that are defined in the Agreement shall have their defined meanings when
used herein.

 

As
collateral security for the due and punctual payment of the Advances made or to
be made under the above Agreement in accordance with the terms thereof, and all
other Obligations of the Borrower or the Trustee to Sallie Mae, whether now or
in the future existing, the Trustee and the Borrower hereby grant to Sallie
Mae, its successors and assigns a security interest in, and pledge to Sallie
Mae, all upon the terms more fully set forth in the Agreement, the
below-described personal property owned by the Trustee or the Borrower, whether
now or hereafter existing or now owned by the Trustee or the Borrower or
hereafter acquired, wherever located (all such property being in this
instrument called the “Security”), namely:

 

(i)
All education loans from time to time legally owned by the Trustee and
beneficially owned by the Borrower that were or are hereafter made pursuant to
the Higher Education Act of 1965, as amended (“Loans”), along with all documentation
related thereto and all rights of the Trustee and the Borrower with respect to
such Loans, including all payments and rights to receive payment with respect
thereto, which Loans may be identified in the records maintained by Sallie Mae,
Inc. or its successor, or by any other servicer of such Loans, as being legally
owned by the Trustee and beneficially owned by the Borrower;

 

(ii)
All guarantee or insurance payments with respect to the Loans and all interest
earned on such Loans or on such payments, along with all documentation related
thereto and all rights of the Trustee and the Borrower with respect to any such
guarantee or insurance payments;

 

(iii)
All grants, contributions, or payments that may be received from any
department, agency, or instrumentality of the United States with respect to the
Loans, including without limitation any supplemental payments and other
benefits payable in respect of such Loans under applicable federal or state
law, regulations, or rulings or decisions of the Secretary of Education or of
any guarantor, or any instrumentality or official thereof;

 

(iv)
All rights of the Trustee and the Borrower in and to any origination or
servicing agreements relating to any Loans;

 

(v)
Any instruments, documents, or chattel paper (as defined in the Uniform
Commercial Code) from time to time delivered to Sallie Mae in pledge in
accordance with the Agreement;

 

1

 

ANNEX E

 

[Alternate for UCC-1 When Eligible Lender Trustee is Involved]

 

Description of Collateral to Be Used in Completing Form UCC-1

 

(i) All education loans from
time to time legally or beneficially owned by the Debtor that were or are
hereafter made pursuant to the Higher Education Act of 1965, as amended (“Loans”),
along with all documentation related thereto and all rights of the Debtor with
respect to such Loans, including all payments and rights to receive payment
with respect thereto, which Loans may be identified in the records maintained
by Sallie Mae, Inc. or its successor, or by any other servicer of such Loans,
as being legally or beneficially owned by the Debtor;

 

(ii) All guarantee or
insurance payments with respect to the Loans and all interest earned on such
Loans or on such payments, along with all documentation related thereto and all
rights of the Debtor with respect to any such guarantee or insurance payments;

 

(iii) All grants,
contributions, or payments that may be received from any department, agency, or
instrumentality of the United States with respect to the Loans, including
without limitation any supplemental payments and other benefits payable in
respect of such Loans under applicable federal or state law, regulations, or
rulings or decisions of the Secretary of Education or of any guarantor, or any instrumentality
or official thereof;

 

(iv) All rights of the
Debtor in and to any origination or servicing agreements relating to any Loans;

 

(v) Any instruments,
documents, or chattel paper (as defined in the Uniform Commercial Code) from
time to time delivered to the secured party in pledge in accordance with the
Revolving Financing Agreement dated as of
                        
20     , among Walden University, Inc., Wells Fargo Bank,
National Association, solely in its capacity as eligible lender trustee for
Walden University, Inc., and the secured party;

 

(vi) Any and all depository
or other accounts into which the secured party deposits the proceeds of
Advances made under the Financing Agreement; and

 

(vii) Any and all proceeds,
and proceeds of proceeds, of all of the foregoing (including any proceeds of
insurance or guarantees).

 

1

 

ANNEX F

 

SERVICER OPERATIONS REPORT

INSTITUTIONAL FINANCE DEPARTMENT

 

Borrower:

 

Period Ending:

 

Date Completed: 

 

Completed By: 

 

I. Default Claim Activity:

 

a.
Number filed greater than 270 days delinquent:

 

II. Rejected Claim Activity:

 

a.   Number of new rejects in
month:

 

b.   Number of rejects
cured/resolved in month:

 

c.   Number of rejects
outstanding at end of month:

 

2

 

ANNEX G 

Opinion of Counsel to Borrower

 

Sallie Mae, Inc. 

12061 Bluemont Way 

Reston, VA 20190

 

Attention: Legal Department

 

We have acted as legal counsel to
                                                
(the “Borrower”) in connection with that certain Revolving Financing Agreement
(together with all documents to be executed in connection therewith, hereafter
the “Financing Agreement”) dated as of
                                  ,
among the Borrower, [INSERT TRUSTEE], solely in its capacity as eligible lender
trustee for the Borrower, and you (“Sallie Mae”). Terms defined in the
Financing Agreement shall have the same meanings when used in this opinion. In
giving this opinion we have examined copies of the Financing Agreement signed
by the Borrower, originals or copies certified to our satisfaction of all
corporate records of the Borrower, and such other documents, records, and other
matters in our opinion appropriate or necessary to enable us to render our
opinion.

 

Subject
to the qualifications mentioned below, we are of the opinion that;

 

(1)   The Borrower is a
                                  
corporation, duly incorporated,
validly existing, and in good standing under the laws of the State of                              ,
and is duly qualified to
transact operations in all places where such qualification is necessary. The
Borrower has the necessary power and legal authority to enter into and perform
its obligations under the Financing Agreement and any instrument or agreement
required thereunder, and to borrow under the Financing Agreement.

 

(2)   All action necessary for
the due authorization, execution, delivery and performance of the Financing
Agreement by the Borrower and any instrument or agreement required under the Financing
Agreement has been duly taken. When executed by Sallie Mae, the Financing
Agreement shall be the legal, valid and binding agreements of the Borrower
enforceable against it in accordance with their terms, and any instrument or
agreement required under the Financing Agreement has been so authorized and,
when executed and delivered, shall be similarly valid, binding, and
enforceable.

 

(3)   The execution, delivery
and performance by the Borrower of the Financing Agreement and of any
instrument or other agreement required thereunder do not and will not:

 

(i) require any consent or approval of the
Borrower’s shareholders; or

 

(ii) violate any provision of any law,
regulation, order, judgment, determination or award presently in effect having
applicability to the Borrower or to the Borrower’s charter or by-laws; or

 

(iii) result in breach of, or constitute a
default under, any outstanding deed, agreement, lease, or other instrument to
which the Borrower is a party or by which it or any of its assets may be bound
or affected.

 

3

 

(4)   The
Borrower and the Trustee have the full right and legal authority to grant a security
interest in the Security to be pledged pursuant to the Financing Agreement.  Upon the making of an Advance, the security
interest of Sallie Mae in the Security shall be a perfected, enforceable,
prior, and first security interest therein free from all other liens, charges,
encumbrances, and security interests of any kind.

 

(5)   The
making and performance of the Financing Agreement and any instrument or other
agreement required thereunder and the creation of a security interest in favor
of Sallie Mae do not require the authorization, approval, or consent of any governmental
authority.

 

(6)   There
are no actions, suits, or proceedings pending or, to our knowledge, threatened against
or affecting the Borrower or any of the assets of the Borrower before any court
or governmental department, board, agency or instrumentality.

 

The
qualifications to which, this opinion is subject are as follows:

 

(A)   This
opinion is limited to the law of
                                   and
the law of the United States as in effect on the date of this opinion. No
opinion is expressed as to the laws of any other jurisdiction.

 

(B)   We
assume the Financing Agreement has been duly authorized by Sallie Mae and will
be duly executed and delivered by Sallie Mae in accordance with such
authorization.

 

(C)   Our
opinion as to the binding effect of the obligations of the Borrower under the Financing
Agreement and any instrument or other agreement required thereunder is subject
to bankruptcy, insolvency, liquidation, and similar laws generally affecting creditors’
rights.

 

(D)   Our
opinion is subject, to the effect of general principles of equity (regardless
of whether considered in a proceeding in equity or at law).

 

Very
truly yours,

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]